^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vesigenurtucel-L (HS-410)

    i
    Other names: UM-UC-3-gp96-Ig-HLA-A1, HS-410
    Associations

    News

    Trials
    Company:
    Scorpius Holdings
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    almost4years
    Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle invasive bladder cancer. (PubMed, Cancer Epidemiol Biomarkers Prev)
    This study serves as a hypothesis generating report for future studies to evaluate the role of urine cytokines as a predictive biomarker of response to immune treatments.
    Clinical • Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL18 (Interleukin 18)
    |
    vesigenurtucel-L (HS-410)
    4years
    A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT (clinicaltrials.gov)
    P1/2, N=104, Terminated, Heat Biologics | Completed --> Terminated; Inability to accrue due to changing treatment landscape (PD-1 approvals)
    Clinical • Trial termination • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    TILs
    |
    vesigenurtucel-L (HS-410)
    over5years
    A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Heat Biologics
    Clinical • New P1/2 trial • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    TILs
    |
    vesigenurtucel-L (HS-410)